Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IB Open-label, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Combination With Androgen Deprivation Therapy and Other Agents in Subjects With Castrate-resistant Prostate Cancer (CRPC)

NCT03150056 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT03150056
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03150056 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IB Open-label, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Combination With Androgen Deprivation Therapy and Other Agents in Subjects With Castrate-resistant Prostate Cancer (CRPC)
Lead sponsor
GlaxoSmithKline
Phase
Phase 1
Overall status
Terminated
Start date
July 18, 2017
Completion date
June 22, 2021
Enrollment
73 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumours